GRTS - GRTS Class Action Alert: Robbins LLP Reminds Stockholders of the Lead Plaintiff Deadline in the Gritstone bio Inc. Class Action | Benzinga
SAN DIEGO, June 14, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of persons and entities that purchased or otherwise acquired Gritstone bio, Inc. (NASDAQ:GRTS) securities between March 9, 2023 and February 29, 2024. Gritstone is a clinical-stage biotechnology company that engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases.
For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.
The Allegations: Robbins LLP is Investigating Allegations that Gritstone bio, Inc. (GRTS) Misled Investors Regarding the Initiation of its Phase 2b CORAL Study
According to the complaint, in September 2023, Gritstone entered into a contract with the Biomedical Advanced Research and Development Authority ("BARDA") to run a 10,000 participant, randomized Phase 2b double-blinded study to compare the efficacy, safety, and immunogenicity of its COVID-19 vaccine candidate (a samRNA vaccine candidate) with an approved COVID-19 vaccine (the "Phase 2b CORAL Study" or the "Study"). In a press release announcing the Study, the Company stated the Study would be fully funded by BARDA and was expected to ...